ClinicalTrials.gg
Not yet recruitingNCT07914998Vis_Sym_SimUpdated Nov 4, 2026

Visual Symptom Simulator

An interventional study of Visual Simulator in Visual Disturbance, sponsored by University of British Columbia. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by University of British Columbia · Not applicable, Interventional, and Health services research

Updated Nov 4, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Some patients presenting with visual symptoms may have difficulty accurately describing their visual experiences. Symptoms such as blurred vision, diplopia, visual field deficits, and transient visual disturbances are subjective and can be challenging to communicate using words alone. This can create communication barriers and contribute to variability in symptom interpretation, with potential implications for reduced patient satisfaction and uncertainty in clinical evaluation, especially among medical trainees.

This prospective, survey-based feasibility and usability study will have the primary objective of evaluating whether a visual symptom simulator (VSS) improves communication of visual symptoms during neuro-ophthalmology assessment compared with standard history-taking alone, and whether it can be feasibly integrated into routine clinical practice as an adjunct to standard history-taking.

Secondary objectives include: 1) assessing whether the use of a visual simulator improves the clarity of patient-reported visual symptoms and reduces ambiguity during clinical assessment; and 2) exploring its potential role in improving trainees' (medical students, residents, fellows) understanding and interpretation of subjective visual symptoms in neuro-ophthalmology.

Read the detailed description

Research design and methods In collaboration with BCIT, a web-based VSS platform will be developed, with the goal of presenting interactive visual symptom scenarios designed to simulate patient-reported visual experiences.

Participants will include patients 18 years or older who are referred to the Ophthalmology Clinic at St Paul's Hospital (SPH) and Vancouver General Hospital (VGH) Eye Care Center for assessment of one of the following visual complaints: transient visual loss, diplopia, or blurry vision. We will also recruit medical trainees rotating through neuro-ophthalmology services. A control group (standard of care) will be recruited first and will undergo standard clinical interview and neuro-ophthalmological assessment without the VSS. Following finalization of the VSS, patients will be recruited into the VSS intervention group.

Methods of analysis, instruments, and tools The VSS will be the primary intervention tool in the intervention group and will be delivered via a web-based platform. The control group will undergo the standard neuro-ophthalmological examination alone.

Data will be collected using post-clinical and post-intervention surveys completed by both patients and trainees. Surveys primarily consist of Likert-scale items assessing patient satisfaction, as well as trainees' perceived understanding of patient symptoms and confidence in clinical reasoning. A short section at the end of the questionnaires will be available to patients and trainees for qualitative feedback.

Quantitative data will be analyzed using descriptive statistics to compare outcomes between control and intervention groups. Where applicable, subgroup analyses may be performed based on level of training (trainees).

Qualitative data from open-ended survey responses will be reviewed and analyzed for recurring themes.

02

Conditions studied

  • Visual Disturbance
03

In context

Lead sponsor

University of British Columbia is the lead sponsor of 1,339 studies on the registry; 259 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older
  • Referred for neuro-ophthalmology evaluation with assessment of one of the following visual complaints: transient visual loss, diplopia, or blurry vision.

Exclusion criteria

Exclusion Criteria:

- Younger than 18 years

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • No intervention
    Control

    Standard of care

  • Active comparator
    Intervention

    Use of simulator

    Device: Visual Simulator

Interventions

  • DeviceVisual Simulator

    Development of an online visual simulator, to allow accurate representation of visual symptoms

06

What researchers measure

Primary outcomes

  1. Patient survey scores

    Outcome survey will include rating scales of: Overall participant experience, Participant perception of physician understanding, Participant ability to communicate symptoms, Perceived influence on treatment/follow-up/care

    Time frame: Immediately, at the completion of the patient first clinical assessment

Secondary outcomes

  1. Trainee survey

    Outcomes include survey ranking of: Overall Educational Value and Trainee rating of VSS educational usefulness

    Time frame: Immediately, at the completion of the patient consultation

07

Study locations

No study locations are listed for this record.

08

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07914998
Responsible party
Claire Sheldon (MD/PhD, University of British Columbia) — Principal investigator
First posted
Nov 4, 2026
Start date
Oct 30, 2026 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Nov 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion